Study of Edaravone Injection for Treatment of Optic Neuritis in Adults with Aquaporin-4 Antibody

What this Trial Is About

Researchers are investigating the effects of edaravone in treating patients with optic neuritis who are positive for aquaporin-4 antibodies. The study is based on previous findings where edaravone showed benefits in promoting remyelination and protecting nerve fibers in animals with neuromyelitis optica spectrum disorder NMOSD. The goal is to evaluate whether edaravone can improve visual outcomes in affected patients. Participants in this study will receive edaravone injections at a dose of 30 mg three times a day. The study focuses on patients experiencing their first episode of optic neuritis within 30 days before starting treatment. The trial follows patients for 18 months to assess visual acuity and retinal nerve layer changes. There are no placebo or masking elements mentioned. During the study, researchers will monitor best-corrected visual acuity along with structural measurements of the retinal layers, including the ganglion cell-inner plexiform layer and the peripapillary retinal nerve fiber layer. These assessments will help determine the impact of edaravone on vision and retinal health. The total participation period extends to 18 months, throughout which patients will undergo regular evaluations to track treatment effects and safety.

Edaravone in the Treatment of Optic Neuritis